AR119231A1 - Agonistas de il2 - Google Patents

Agonistas de il2

Info

Publication number
AR119231A1
AR119231A1 ARP200101777A ARP200101777A AR119231A1 AR 119231 A1 AR119231 A1 AR 119231A1 AR P200101777 A ARP200101777 A AR P200101777A AR P200101777 A ARP200101777 A AR P200101777A AR 119231 A1 AR119231 A1 AR 119231A1
Authority
AR
Argentina
Prior art keywords
human
functional variant
polypeptide
polynucleotides
wild
Prior art date
Application number
ARP200101777A
Other languages
English (en)
Inventor
Ugur Sahin
Sina Fellermeier-Kopf
Alexander Muik
Mathias Vormehr
Lena Mareen Kranz
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of AR119231A1 publication Critical patent/AR119231A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente se relaciona con variantes de la interleucina-2 (IL2). En particular, la presente se relaciona con un polipéptido que comprende una muteína de IL2 humana o una variante funcional de la IL2 humana, donde la IL2 humana o variante funcional de esta se sustituye de forma tal que se mejora la afinidad con el complejo receptor de IL2 (IL2R). En una realización, la IL2 humana o variante funcional de esta se sustituye además de forma tal que se reduce la afinidad con el complejo receptor de IL2 (IL2R). En una realización, el polipéptido activa células T efectoras sobre células T reguladoras. La presente también se relaciona con polinucleótidos, composiciones farmacéuticas que comprenden los polipéptidos, polinucleótidos, o células hospedadoras, métodos terapéuticos o profilácticos de tratamiento usando los polipéptidos, polinucleótidos, células hospedadoras o composiciones farmacéuticas y preparaciones médicas que comprenden los polipéptidos, polinucleótidos, células hospedadoras o composiciones farmacéuticas. Reivindicación 1: Un polipéptido que comprende una muteína de interleucina-2 (IL2) humana o de una variante funcional de IL2 humana, donde la IL2 humana o la variante funcional de esta se sustituye en al menos la posición 80 (leucina), posición 81 (arginina), posición 85 (leucina) y posición 92 (isoleucina) en comparación con la IL2 humana de tipo salvaje y se enumera de conformidad con la IL2 humana de tipo salvaje, donde la sustitución potencia la afinidad para el complejo receptor bg IL2 (IL2Rbg) y donde la IL2 humana o la variante funcional de esta no se sustituye en la posición 86 (isoleucina) en comparación con la IL2 humana de tipo salvaje y se enumera de conformidad con la IL2 humana de tipo salvaje. Reivindicación 30: Una composición farmacéutica que comprende el polipéptido de cualquiera de las reivindicaciones 1 a 23, el polinucleótido de la reivindicación 24 ó 25, o la célula hospedadora de la reivindicación 26. Reivindicación 31: Un método para tratar a un sujeto que comprende administrar al sujeto el polipéptido de cualquiera de las reivindicaciones 1 a 23, el polinucleótido de la reivindicación 24 ó 25, la célula hospedadora de la reivindicación 26 o la composición farmacéutica de la reivindicación 30.
ARP200101777A 2019-06-24 2020-06-23 Agonistas de il2 AR119231A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2019066648 2019-06-24

Publications (1)

Publication Number Publication Date
AR119231A1 true AR119231A1 (es) 2021-12-01

Family

ID=71103401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101777A AR119231A1 (es) 2019-06-24 2020-06-23 Agonistas de il2

Country Status (16)

Country Link
US (1) US20220356223A1 (es)
EP (1) EP3986916A1 (es)
JP (1) JP2022539543A (es)
KR (1) KR20220027864A (es)
CN (1) CN114450296A (es)
AR (1) AR119231A1 (es)
AU (1) AU2020308592A1 (es)
BR (1) BR112021026147A2 (es)
CA (1) CA3142911A1 (es)
CL (1) CL2021003437A1 (es)
CO (1) CO2021017639A2 (es)
CU (1) CU20210105A7 (es)
IL (1) IL288536A (es)
MX (1) MX2021015852A (es)
TW (1) TW202115105A (es)
WO (1) WO2020260270A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20220020A7 (es) 2022-03-18 2023-12-07 Ct Inmunologia Molecular Muteínas derivadas de la interleucina-2 humana con actividad superagonista
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
PT2316852E (pt) 2002-11-08 2014-06-23 Ablynx Nv Anticorpos de domínio único estáveis
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
CA2663042A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
BRPI0821924A2 (pt) 2007-12-27 2015-07-07 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e seu uso
ES2620285T3 (es) 2008-05-02 2017-06-28 Novartis Ag Moléculas de unión con base en fibronectina mejorada y usos de las mismas
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
EA022983B1 (ru) 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Белки на основе структурного домена фибронектина, связывающие pcsk9
DK3489255T3 (da) * 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CN106659757B (zh) * 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
AU2019311233A1 (en) * 2018-07-24 2021-01-21 BioNTech SE IL2 agonists

Also Published As

Publication number Publication date
EP3986916A1 (en) 2022-04-27
MX2021015852A (es) 2022-02-03
WO2020260270A1 (en) 2020-12-30
US20220356223A1 (en) 2022-11-10
KR20220027864A (ko) 2022-03-08
CL2021003437A1 (es) 2022-09-23
AU2020308592A1 (en) 2022-01-06
CN114450296A (zh) 2022-05-06
TW202115105A (zh) 2021-04-16
JP2022539543A (ja) 2022-09-12
IL288536A (en) 2022-01-01
CO2021017639A2 (es) 2022-01-17
CA3142911A1 (en) 2020-12-30
BR112021026147A2 (pt) 2022-05-10
CU20210105A7 (es) 2022-08-09

Similar Documents

Publication Publication Date Title
BR112021000811A8 (pt) Agonistas de il2
BR112021019076A2 (pt) Composição farmacêutica e formulação para injeção subcutânea compreendendo uma variante de hialuronidase ph20 humana
AR085741A1 (es) POLIPEPTIDOS QUE COMPRENDEN VARIANTES DE UNA REGION Fc
AR119231A1 (es) Agonistas de il2
BRPI0607326A2 (pt) composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento
BR112018076437A2 (pt) interferon porcino peguilado e seus métodos de utilização
MX2018013622A (es) Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada.
AR099976A1 (es) Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4
BR112018070852A2 (pt) composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
US20220370560A1 (en) Ptd-smad7 therapeutics
EA202192555A1 (ru) Комбинированная терапия для лечения рака
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
PH12019550241A1 (en) Mic-1 compounds and uses thereof
BR112017013300A2 (pt) alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
BR112019009511A2 (pt) polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.
BR112017022506A2 (pt) composições compreendendo aminoácidos para uso no tratamento de mucosites em pacientes com neoplasia submetidos a terapia de radiação e / ou quimioterapia
CO2021000210A2 (es) Apirasas solubilizadas, métodos y usos
BR112021019979A2 (pt) Tratamento envolvendo interleucina-2 (il2) e interferon (ifn)
BR112022003633A2 (pt) Métodos para produção de arginase 1 recombinante humana e usos da mesma
BR112017022390A2 (pt) composição farmacêutica
NZ748614A (en) Fusion protein comprising ccl3 variant and use thereof cross-reference to related applications
JP2015515855A5 (es)
BR112022010063A2 (pt) Composição para tratamento anticâncer, compreendendo células nk e proteína de fusão que compreende proteína il-2 e proteína cd80
EA202092366A1 (ru) Применение происходящих из pedf коротких пептидов при лечении остеоартрита